Navigation Links
For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer, Surveyed Oncologists Indicate that Improved Symptom Control and Quality of Life is one of the Greatest Unmet Needs
Date:6/5/2013

BURLINGTON, Mass., June 5, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that symptom control and quality of life is one of the factors the most influences surveyed U.S. and European oncologists' treatment decisions for second- and subsequent-line metastatic castrate-resistant prostate cancer (mCRPC), and that improved symptom control and quality of life is one of the greatest unmet needs in this indication. Interviewed thought leaders expressed optimism that cabozantinib (Exelixis's Cometriq) and radium-223 (Algeta/Bayer HealthCare's Xofigo) will have an advantage over sales-leading abiraterone (Johnson & Johnson/Janssen Biotech/Janssen-Cilag's Zytiga) on this attribute and will help to partially fulfill the large unmet need.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The DecisionBase 2013 report entitled Prostate Cancer (Second- and Subsequent-Line Metastatic Castrate-Resistant): What Advantages Do Surveyed Oncologists and Payers Believe Emerging Therapies Have to Offer in Order to Gain Traction in This Crowded and Competitive Market finds that surveyed U.S. managed care organization pharmacy directors are most willing to grant favorable formulary status to new second- and subsequent-line mCRPC therapies offering  increased median overall survival (MOS) over currently available treatment options. Nevertheless, nearly half of the surveyed payers indicated that they would not reimburse a new therapy priced the same as enzalutamide (Medivation/Astellas Pharma's Xtandi) or higher that offered a three-month improvement in median overall survival over enzalutamide, most commonly stating insufficient clinical benefit to grant reimbursement
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Johnson & Johnson to Host Analyst Conference Call on Second-Quarter Results
2. Hospira to Host Conference Call for Second-quarter 2012 Results
3. Lilly Confirms Date and Conference Call for Second-Quarter 2012 Financial Results Announcement
4. Boston Scientific to Announce Second-Quarter 2012 Financial Results on July 26
5. Lilly Reports Second-Quarter 2012 Results, Raises 2012 EPS Guidance
6. Hospira Reports Second-Quarter 2012 Results
7. Star Scientific, Inc. Files Second-Quarter Financial Report (Net Sales and Gross Profits Continue to Increase) and Updates Research and Marketing Activities
8. WuXi PharmaTech Announces Second-Quarter 2012 Results
9. Cardinal Health Reports Fiscal 2013 Second-Quarter Results
10. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
11. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 According ... by Composition of Material, Application (Healthcare, Homeland security, ... Product (Personal Instrument, Hand-Held Instruments, Fixed, and Installed ... to 2013 - 2020", published by MarketsandMarkets, the Scintillator Market ... 5.62% from 2014 to 2020, and reach $479.16 ...
(Date:7/11/2014)... On Thursday, July 10, 2014, the NASDAQ ... Average finished the day 0.42% lower at 16,915.07, and the ... broad based as eight out of ten sectors ended the ... ended the day at 711.88, down 0.02%, while the index ... initiated coverage on the following equities: Covidien PLC (NYSE: ...
(Date:7/11/2014)... LONDON , July 11, 2014 /PRNewswire/ ... of visitors to Safety & Health Expo ... by the move to London ... senior management attending exhibition.     ... (Photo: http://photos.prnewswire.com/prnh/20140711/696892-a ) ...
Breaking Medicine Technology:Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4
(Date:7/12/2014)... 2014 Recently, Fadhits.com, a well-known wedding dress ... long graduation dresses to its product line. In ... loyal clients. It wants to bring more benefits for its ... offered at discounted prices, up to 72% off. , As ... working hard. Its online shop is a good place for ...
(Date:7/12/2014)... New York, NY (PRWEB) July 12, 2014 ... experienced steady growth over the past five years, buoyed ... the agricultural sector's supply management system. “Eggs are a ... a result, per capita egg consumption generally grows in ... IBISWorld Industry Analyst Will McKitterick. Furthermore, demand for new ...
(Date:7/12/2014)... Fresh off their respective performances in the 2014 World Cup, ... at Sun Life Stadium in an international friendly. The World ... stars in the world of football in Colombian and Brazilian ... some of the best talent in the world in early ... team in the world according to the Fédération Internationale de ...
(Date:7/12/2014)... report, "Phthalic Anhydride and Derivatives (Plasticizers, Unsaturated Polyester Resins, ... Trends & Forecast to 2018," defines and segments phthalic ... and value. The report also estimates the demand and ... anhydride is projected to grow from an estimated $6,130.55 ... a CAGR of 5.24% from 2013 to 2018. , ...
(Date:7/12/2014)... 12, 2014 The ... Vascular Devices Market by Angioplasty Balloon ... (IVUS, OCT), IVC Filter (Retrievable), Endovascular ... analyzes and studies the major market ... U.S. and Canada. , Browse 108 ...
Breaking Medicine News(10 mins):Health News:New Collection of Long Graduation Dresses Revealed by Fadhits.com 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 2Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 2Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 3Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 4Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 5
... To be joined by special guests Ringo Starr, Sheryl Crow, ... and Jim JamesTickets go on sale Monday, March 9, at ... Paul McCartney and special guests Ringo Starr, Sheryl Crow, ... Bettye LaVette, and Jim James will perform at the David ...
... CARDIFF, Calif., March 4 Rapid Fire Marketing, (Pink ... Inc., a development stage software firm utilizing the latest ... technology works off a wireless headset that responds to ... power of your own mind. The technology has ...
... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced ... of BioMarin, will present a company update at the Barclays ... 2009 at 2:30 p.m. ET. Interested parties may access ... investor section of the BioMarin website, www.BMRN.com . ...
... assistant (MCA), featuring touch screen input. The MediSlate was designed ... whether that is a hospital ward, medical clinic or emergency room. ... ... TabletKiosk ®, a leader in mobile computing solutions, today announced ...
... The Johnson Institute has transferred key programs and ... Advocacy under an agreement reached last week by ... )The transfer ensures a continuation of the Johnson ... and possibility of recovery from alcoholism and dependence ...
... will be held Saturday, October 17 at , ... Chapter of the Juvenile Diabetes Research Foundation (JDRF) has announced ... Monye Connolly, will serve as the Corporate Chair for its ... The event is scheduled in Atlanta at Centennial ...
Cached Medicine News:Health News:Paul McCartney to Headline Benefit Concert for David Lynch Foundation at Radio City Music Hall on Saturday, April 4 2Health News:BioMarin to Present at the Barclays Capital Global Healthcare Conference 2Health News:TabletKiosk Introduces the MediSlate™ MCA i1040XT: A Mobile Clinical Assistant (MCA) with Touch Screen Input 2Health News:TabletKiosk Introduces the MediSlate™ MCA i1040XT: A Mobile Clinical Assistant (MCA) with Touch Screen Input 3Health News:TabletKiosk Introduces the MediSlate™ MCA i1040XT: A Mobile Clinical Assistant (MCA) with Touch Screen Input 4Health News:TabletKiosk Introduces the MediSlate™ MCA i1040XT: A Mobile Clinical Assistant (MCA) with Touch Screen Input 5Health News:Johnson Institute Transfers Key Programs and Products to Hazelden Foundation 2Health News:Juvenile Diabetes Research Foundation Names Monye Connolly Corporate Chair for its Annual Walk to Cure Diabetes 2
Used for placement of choledochoscopes, cholangiography catheters and other instruments. Supplied sterile in peel-open packages. Intended for one-time use....
Used for common bile duct exploration. Supplied sterile in peel-open packages. Intended for one-time use....
... Marker directly to the biopsy site helps ... performed. ,The MICROMARK® II Tissue Marker is ... for use with the MAMMOTOME Biopsy System. ... site after a biopsy with the MAMMOTOME ...
... A biopsy with the ... an effective, minimally invasive procedure ... patient management.,Using computer-generated images to ... more accurately pinpoint and map ...
Medicine Products: